2319609-67-9

KY19334 is a small molecule that activates the Wnt/β-catenin pathway by inhibiting the CXXC5–Dvl interaction and accelerates wound healing in diabetic mice. By restoring the suppressed Wnt/β-catenin signaling and thereby inducing the expression of its target genes, KY19334 enhances the wound-healing capacity of diabetic mice. Furthermore, KY19334 induces angiogenesis in mice with hindlimb ischemia.

KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes.

[1] Lee, Soung-Hoon, et al. “Novel Small Molecules Downregulate CDK1 Expression and Inhibit Wnt/β-Catenin Signaling in Cutaneous Squamous Cell Carcinoma by Targeting Its Distinct Tumor-Specific Cellular Landscape.” Experimental and Molecular Medicine, 57 9, 2025, pp. 1996–2009,https://doi.org/10.1038/s12276-025-01532-y.
[2] Kim, Eunhwan, et al. “Inhibiting the Cytosolic Function of CXXC5 Accelerates Diabetic Wound Healing by Enhancing Angiogenesis and Skin Repair.” Experimental and Molecular Medicine, 55 8, 2023, pp. 1770–82, https://doi.org/10.1038/s12276-023-01064-3.